A representative participant performing a Valsalva maneuver while checking the real-time respiratory pressure indicator. by Eun-Seon Yang (19751340)

Subjects:

Raw data. by Saeedeh Abbasi (9423189)

Subjects:

Data. by Saeedeh Abbasi (9423189)

Subjects:

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

Table 1_Fertilization decreases the effect of ammonium nitrogen on microorganisms in Chinese Carex tibetikobresia meadows during rest-grazing.docx by Xuanbo Zhou (19374205)

Sociodemographic characteristics. by Hea Ree Park (10769827)

Subjects:

Study flow chart. by Hea Ree Park (10769827)

Subjects:

Determination of Cleaved Caspase-3 positive cells in MTA and Harvard treated groups. by Meltem Karahan (19713246)

Subjects:

Dose-dependent effect of dental materials on hatching rate of zebrafish embryos and larvae at the indicated time points. by Meltem Karahan (19713246)

Subjects:

Dose-dependent effect of dental materials on the survival of zebrafish embryos and larvae at the indicated time points. by Meltem Karahan (19713246)

Subjects:

The apoptic effects of dental materials on zebrafish larvae. by Meltem Karahan (19713246)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: